New weight loss pill ZT006 enters first human tests

NCT ID NCT07307638

Completed Disease control Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested ZT006, an experimental daily pill for weight loss, in 94 healthy, overweight, and obese adults. The study checked safety, how the body processes the drug, and the effect of food on absorption. Participants received single or multiple doses, with some also testing the drug after a high-fat meal. The goal is to see if ZT006 is safe enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZT006 (an oral GLP-1 drug)
What this could lead to: If successful, this could lead to a new daily pill for weight management, offering an alternative to injectable GLP-1 drugs.
What could go wrong: This is a very early Phase 1 trial with only 94 healthy participants, focused on safety and dosing. It is not yet tested for long-term weight loss or in people with obesity-related health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT , OBESITY

Contacts and locations

Locations

The Second Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230601, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.